Satraplatin
- Generic Name
- Satraplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H22Cl2N2O4Pt
- CAS Number
- 129580-63-8
- Unique Ingredient Identifier
- 8D7B37T28G
- Background
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
- Indication
Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- William K. Oh
- Target Recruit Count
- 13
- Registration Number
- NCT01289067
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT01259479
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Satraplatin and Prednisone to Treat Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00634647
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸Associates in Oncology and Hematology, Rockville, Maryland, United States
Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00499694
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Yale University
- Target Recruit Count
- 15
- Registration Number
- NCT00473720
- Locations
- 🇺🇸
Yale University, Comprehensive Cancer Center, New Haven, Connecticut, United States
A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Agennix
- Target Recruit Count
- 100
- Registration Number
- NCT00370383
- Locations
- 🇺🇸
Highlands Oncology Group, Bentonville, Ohio, United States
🇺🇸Signal Point Hematology/Oncology, Middleton, Ohio, United States
🇨🇦Princess Margaret Hospital, Toronto, Canada
A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Agennix
- Target Recruit Count
- 25
- Registration Number
- NCT00313456
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
- Conditions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Agennix
- Target Recruit Count
- 40
- Registration Number
- NCT00265655
- Locations
- 🇺🇸
US Oncology, Dallas, Texas, United States
Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Agennix
- Target Recruit Count
- 20
- Registration Number
- NCT00093132
- Locations
- 🇺🇸
Southwestern Medical Center, Dallas, Texas, United States
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
- Conditions
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Agennix
- Registration Number
- NCT00069745
- Locations
- 🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Texas Cancer Center at Medical City, Dallas, Texas, United States
🇩🇪Marienhospital II, Herne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.